medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2011, Número 3

<< Anterior Siguiente >>

Biotecnol Apl 2011; 28 (3)


Conocimientos novedosos sobre la influencia de la proporción entre las proteínas estructurales del virus de la hepatitis C para la inducción de una respuesta inmune protectora en un modelo de reto con virus sustituto

Musacchio A, Martínez G, Alvarez L, Guerra I, Acosta N, Amador Y, Pérez A, Soria Y, Puentes P, Dueñas S

Idioma: Ingles.
Referencias bibliográficas: 14
Paginas: 180-182
Archivo PDF: 181.42 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Caruntu FA, Benea L. Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006; 15:249-56.

  2. Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004; 53:1504-8.

  3. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436:961-6.

  4. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999; 117:933-41.

  5. Houghton M, Choo QL, Chien D, Kuo G, Weiner A, Coates S, et al. Development of an HCV vaccine. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, editors. Viral hepatitis and liver diseases. Turín: Minerva Medica; 1997. p. 656-9.

  6. Li P, Wan Q, Feng Y, Liu M, Wu J, Chen X, et al. Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine. 2007;25:1544-51.

  7. Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine. 2004;22:991-1000.

  8. Martinez-Donato G, Acosta-Rivero N, Morales-Grillo J, Musacchio A, Vina A, Alvarez C, et al. Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast. Biochem Biophys Res Commun. 2006;342:625-31.

  9. Acosta-Rivero N, Poutou J, Alvarez-Lajonchere L, Guerra I, Aguilera Y, Musacchio A, et al. Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant. Biol Res. 2009;42:41-56.

  10. Musacchio A, Duenas-Carrera S, Alvarez-Lajonchere L, Acosta-Rivero N, Martinez-Donato G, Guirola M, et al., inventors; Center for Genetic Engineering and Biotechnology, asignee. Vaccine composition against hepatitis c virus. International patent WO2006024240. 2006 Mar 9.

  11. Krishnadas DK, Ahn JS, Han J, Kumar R, Agrawal B. Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms. Int Immunol. 2010;22:491-502.

  12. Martínez-Donato G, Musacchio A, Alvarez-Lajonchere L, Acosta-Rivero N, Amador Y, Guerra I, et al. Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction. Biotechnol Appl Biochem. 2010;56:111-8.

  13. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ and Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA. 2003;100:6753-8.

  14. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA. 2007;104:8449-54.




2020     |     www.medigraphic.com